E. Gabriela Chiorean

20.3k total citations · 2 hit papers
209 papers, 7.1k citations indexed

About

E. Gabriela Chiorean is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, E. Gabriela Chiorean has authored 209 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 172 papers in Oncology, 67 papers in Cancer Research and 51 papers in Pulmonary and Respiratory Medicine. Recurrent topics in E. Gabriela Chiorean's work include Pancreatic and Hepatic Oncology Research (88 papers), Colorectal Cancer Treatments and Studies (50 papers) and Cancer Genomics and Diagnostics (48 papers). E. Gabriela Chiorean is often cited by papers focused on Pancreatic and Hepatic Oncology Research (88 papers), Colorectal Cancer Treatments and Studies (50 papers) and Cancer Genomics and Diagnostics (48 papers). E. Gabriela Chiorean collaborates with scholars based in United States, Spain and Canada. E. Gabriela Chiorean's co-authors include Peter J. O’Dwyer, Gregory L. Beatty, Ursina Teitelbaum, Drew A. Torigian, Babak Saboury, Robert H. Vonderheide, Weijing Sun, Leslie L. Sharp, Richard D. Huhn and Dongguang Li and has published in prestigious journals such as Science, Journal of Clinical Oncology and Blood.

In The Last Decade

E. Gabriela Chiorean

198 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

2011 1.3k citations Gregory L. Beatty, E. Gabriela Chiorean et al. profile →
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma

2021 175 citations Davendra Sohal, Syed A. Ahmad et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Gabriela Chiorean United States	42	4.7k	2.1k	1.7k	1.7k	1.5k	209	7.1k
Michael J. Pishvaian United States	40	3.8k 0.8×	1.9k 0.9×	831 0.5×	1.5k 0.9×	1.1k 0.7×	216	5.8k
Raanan Berger Israel	34	4.2k 0.9×	2.2k 1.0×	1.6k 1.0×	1.2k 0.7×	1.9k 1.3×	160	7.2k
Kyriakos P. Papadopoulos United States	47	3.8k 0.8×	4.3k 2.0×	1.4k 0.8×	1.2k 0.7×	1.5k 1.0×	324	8.1k
Niels Reinmuth Germany	43	5.0k 1.1×	2.9k 1.4×	851 0.5×	1.5k 0.9×	2.9k 1.9×	196	7.9k
Young Kwang Chae United States	40	3.1k 0.7×	2.6k 1.2×	820 0.5×	1.7k 1.0×	1.9k 1.2×	274	6.4k
Todd M. Bauer United States	50	5.4k 1.2×	2.9k 1.4×	1.4k 0.8×	1.5k 0.9×	4.2k 2.7×	264	8.6k
Helen Gogas Greece	49	6.5k 1.4×	3.8k 1.8×	2.2k 1.3×	1.1k 0.7×	1.1k 0.7×	330	9.2k
Mark N. Stein United States	40	2.5k 0.5×	2.3k 1.1×	880 0.5×	1.3k 0.8×	2.1k 1.4×	243	5.8k
Wells A. Messersmith United States	52	5.3k 1.1×	4.3k 2.0×	1.1k 0.6×	1.7k 1.0×	1.8k 1.2×	298	9.5k
Petri Bono Finland	44	3.9k 0.8×	2.7k 1.3×	1.3k 0.7×	1.6k 0.9×	2.4k 1.6×	156	7.5k

Countries citing papers authored by E. Gabriela Chiorean

Since Specialization

Citations

This map shows the geographic impact of E. Gabriela Chiorean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Gabriela Chiorean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Gabriela Chiorean more than expected).

Fields of papers citing papers by E. Gabriela Chiorean

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Gabriela Chiorean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Gabriela Chiorean. The network helps show where E. Gabriela Chiorean may publish in the future.

Co-authorship network of co-authors of E. Gabriela Chiorean

This figure shows the co-authorship network connecting the top 25 collaborators of E. Gabriela Chiorean. A scholar is included among the top collaborators of E. Gabriela Chiorean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Gabriela Chiorean. E. Gabriela Chiorean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Safyan, Rachael A. & E. Gabriela Chiorean. (2025). Updates on molecular targets and clinical trials with targeted therapies for pancreatic cancer. Surgical Oncology. 63. 102268–102268.

Raghav, Kanwal, Katherine A. Guthrie, Benjamin Tan, et al.. (2025). Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial. Journal of Clinical Oncology. 43(11). 1348–1357. 2 indexed citations

Patel, Sameer H., Davendra Sohal, Katherine A. Guthrie, et al.. (2025). Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505. Cancer. 131(4). e35759–e35759. 2 indexed citations

Chen, Eric X., Petr Kavan, Mustapha Tehfé, et al.. (2024). Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clinical Colorectal Cancer. 23(2). 183–193. 2 indexed citations

Chiorean, E. Gabriela, Aude G. Chapuis, Andrew L. Coveler, et al.. (2024). Abstract A003: Preliminary safety results from a phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T cell receptor (TCR) (FH-TCR TMSLN) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDA). Cancer Research. 84(2_Supplement). A003–A003.

King, Gentry Teng, R J Berg, Melissa C. Stoppler, et al.. (2024). Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations.. Journal of Clinical Oncology. 42(3_suppl). 557–557. 1 indexed citations

Wattenberg, Max M., Ignacio Garrido‐Laguna, Jesse Lee, et al.. (2024). Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Gastroenterology. 166(6). 1114–1129. 11 indexed citations

Kim, Richard D., Mustapha Tehfé, Petr Kavan, et al.. (2024). Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D. Clinical Colorectal Cancer. 23(2). 118–127.e6. 8 indexed citations

Zhen, David B., et al.. (2023). The role of molecular testing in pancreatic cancer. Therapeutic Advances in Gastroenterology. 16. 1108354432–1108354432. 7 indexed citations

10.

King, Gentry Teng, Stacey A. Cohen, E. Gabriela Chiorean, et al.. (2023). 114P Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers. Annals of Oncology. 34. S225–S225. 4 indexed citations

11.

Jia, Yanfei, Dongsheng Gu, Jun Wan, et al.. (2018). The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer. Oncogene. 38(10). 1764–1777. 60 indexed citations

12.

Chiorean, E. Gabriela, Patricia LoRusso, Robert Matthew Strother, et al.. (2015). A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors. Clinical Cancer Research. 21(12). 2695–2703. 114 indexed citations

13.

Beatty, Gregory L., Drew A. Torigian, E. Gabriela Chiorean, et al.. (2013). A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. 19(22). 6286–6295. 364 indexed citations

14.

Gu, Dongsheng, Hailan Liu, Gloria H. Su, et al.. (2013). Combining Hedgehog Signaling Inhibition with Focal Irradiation on Reduction of Pancreatic Cancer Metastasis. Molecular Cancer Therapeutics. 12(6). 1038–1048. 47 indexed citations

15.

LoRusso, Patricia, Karthik Venkatakrishnan, E. Gabriela Chiorean, et al.. (2013). Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. Investigational New Drugs. 32(1). 160–170. 13 indexed citations

16.

Song, Bing, X. Shawn Liu, Shihuan Kuang, et al.. (2012). Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer. Molecular Cancer Therapeutics. 12(1). 58–68. 62 indexed citations

17.

Tolcher, Anthony W., Christopher J. Sweeney, K. Papadopoulos, et al.. (2011). Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin. Clinical Cancer Research. 17(2). 363–371. 67 indexed citations

18.

Weiss, Glen J., Jeffrey R. Infante, E. Gabriela Chiorean, et al.. (2011). Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 17(9). 2997–3004. 122 indexed citations

19.

Galsky, Matthew D., Luis H. Camacho, E. Gabriela Chiorean, et al.. (2011). Retrospective Analysis of Satraplatin in Patients with Metastatic Urothelial Cancer Refractory to Standard Platinum-Based Chemotherapy. Clinical Genitourinary Cancer. 9(1). 27–30. 4 indexed citations

20.

Chiorean, E. Gabriela & Jeffrey S. Miller. (2001). The Biology of Natural Killer Cells and Implications for Therapy of Human Disease. Journal of Hematotherapy & Stem Cell Research. 10(4). 451–463. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact